SUBSCRIBE

Breaking News on Supplements, Health & Nutrition - Europe US edition | APAC edition

News > Suppliers

Read more breaking news

 

 

Nutra Pharma to buy biotech company

02-May-2002

Nutra Pharma, the US company which develops proprietary technologies for the manufacture of complex medicinal botanical extracts, has signed a letter of intent to Bio Therapeutics, a drug delivery platform producer.

The acquisition adds a complete line of patented and patent-pending drug delivery platforms and drug candidates to Nutra Pharma's portfolio, which already includes the wound healing herbal extract WD-667. Bio Therapeutics' main product is focused on the treatment of multiple sclerosis.

Bio Therapeutics, founded in 1984 as Phylomed, has two primary technology platforms from which it is developing multiple products. The first is a proprietary and patented method for altering the three-dimensional structure of certain proteins and peptides which results in the preservation of receptor-binding characteristics.

The binding of specialised signalling proteins and peptides to cell surface receptors is an important part in the pathogenesis and progression of many different diseases. By modifying peptides which do not activate the normal biochemical pathways necessary for disease progression, powerful therapeutic agents could restore normal function to diseased tissue or exert a beneficial immunomodulatory effect.

The second major technology platform is an innovative aerosolised drug delivery system which greatly enhances the permeability of the mucous membranes found in the mouth and throat, thus allowing for the easy and efficient systemic delivery into the bloodstream of a much wider variety of proteins and peptides without frequent and painful injections.

"Bio Therapeutics has invested millions in research and development, obtained extensive patent coverage, built production facilities and made substantial progress in clinical trials," said Suzanne Mundschenk, chief executive officer of Bio Therapeutics. "We look forward to commercialising our products and technology through Nutra Pharma's leadership."

The company's research has yielded a breakthrough class of therapeutic peptides collectively referred to as 'Immunokines'. This peptide technology has created new opportunities for the relief and treatment of a variety of devastating neurological and viral disorders, most of which are currently without satisfactory therapies.

Trials of the product on multiple sclerosis sufferers have been highly successful, with one wheelchair-bound MS patient able to get up and walk unassisted only 30 minutes after administration of Alpha-Immunokine, the company claimed. Immunokine has been shown to be beneficial in the treatment of cancers, HIV infections, and herpes, as well as viral diseases specific to animals. Immunokine also has the potential to treat hepatitis C infections in humans.

"Bio Therapeutics brings 18 years of R&D and product development that has yielded four patents and two patents-pending," said Dr Michael Flax, chief executive officer of Nutra Pharma. "Nutra Pharma will aggressively commercialise Bio Therapeutics' drug candidates and actively pursue licensing its extensive patent coverage of protein modification, protein drug delivery and inhalator delivery system."

Live Supplier Webinars

Polyphenols tipped to become the way to innovate in Sports Nutrition
Fytexia
Alpha & Omega in Sports Nutrition – Using Omega 3’s and A-GPC to improve performance and recovery.
KD Pharma
Orally bioavailable standardized botanical derivatives in sport nutrition: special focus on recovery in post-intense physical activities
Indena
Collagen in motion: move freely and keep your injuries in check
Leading manufacturer of gelatine and collagen peptides
Life’s too short for slow proteins. Whey proteins hydrolysates: Fast delivery for enhanced performance
Arla Foods Ingredients
What it Takes to Compete and Win in Today’s Sports Nutrition Market
Capsugel
Sports Nutrition Snapshot: Key regional drivers and delivery format innovations
William Reed Business Media
Gutsy performance: How can microbiome modulation help athletes and weekend warriors
William Reed Business Media
Pushing the boundaries: Where’s the line between ‘cutting edge nutrition’ and doping
William Reed Business Media

On demand Supplier Webinars

High-amylose maize starch may reduce the risk of type 2 diabetes: what does this qualified health claim mean?
Ingredion
Balancing Innovation and Risk in Sports Nutrition Ingredients
NSF-International
Explaining bio-hacking: is there a marketing opportunity for food companies?
William Reed Business Media
Personalized Nutrition – how an industry can take part in shaping the future of Nutrition
BASF Nutrition & Health
Find out Nutritional and ingredient lifecycle solutions and strategies!
Roquette
Is the time rIpe for I-nutrition?
William Reed Business Media
The Advantage of Outsourcing Fermentation-based Manufacturing Processes
Evonik Health Care
All supplier webinars